

UCLA

Proceedings of UCLA Health

Title

Aortic Dissection in a Patient with Vascular Ehlers-Danlos Syndrome

Permalink

<https://escholarship.org/uc/item/4nj5d409>

Journal

Proceedings of UCLA Health, 21(1)

Authors

Cheong, Kimberly

Kochar, Minisha

Publication Date

2017-05-31

CLINICAL VIGNETTE

Aortic Dissection in a Patient with Vascular Ehlers-Danlos Syndrome

Kimberly Cheong, M.D. and Minisha Kochar, M.D.

A 52-year-old woman was referred for aortic disease. Her mother died suddenly at age 41, and the autopsy showed an aortic dissection. In the past year, the patient's 17-year-old son was diagnosed with a murmur during a routine physical. Transthoracic echocardiogram (TTE) showed no valvular abnormalities, however, detected an incidental ascending aortic aneurysm. Given the family history, the patient's son underwent genetic testing and was found to have vascular Ehlers-Danlos syndrome. Our patient was concerned that she carried the gene and was at risk for aortic aneurysm or dissection.

Aortic dissection is one of the most devastating complications of thoracic aortic disease. The incidence of thoracic aortic dissection as reported in a British study is 6 cases per 100,000.¹ Most dissections are due to medial degeneration of the aorta. This is characterized by loss of elastic fiber and loss and reorganization of smooth muscle cells in this layer as well as proteoglycan deposition.^{2,3} As circumstances occur which increase the tension within the aortic wall, using Laplace's law, wall tension (T) equals pressure (P) multiplied by radius (R), the aorta loses distensibility, which may lead to a dissection.

Dissections can occur independently of aneurysms or as sequelae to aneurysms. Patients with conditions that contribute to the degeneration of the medial layer, including Marfan's syndrome, Loeys-Dietz syndrome, and the vascular form of Ehlers-Danlos as found in this patient and her family, are at increased risk for dissections. Independent of genetic disorders, aortic dissection can also occur when the aorta is subject to physical trauma as in a motor vehicle accidents or falls, in addition to hypertension, which increases the wall stress.

Vascular Ehlers-Danlos is an autosomal dominantly inherited disorder in the gene that encodes the chains of type III collagen (COL3A1), a major protein in the walls of blood vessels and hollow organs.⁴⁻⁶ The initial diagnosis is usually suspected based on family history, arterial rupture or dissection, rupture of the large intestine, or pregnancy complications at a young age. As blood vessels are affected, there is often easy bruising from a young age, sometimes prompting concerns of child abuse in young children. In addition to physical findings, the diagnosis can be made by genetic testing. The median survival rate in patients with vascular Ehlers-Danlos is 48 years, with the major cause of death being arterial dissection. Even when aneurysm or dissection is diagnosed early, the fragility of the tissue often creates difficulty during surgery and can lead to significant post-operative complications.⁵⁻⁸

In the absence of symptoms, an aortic aneurysm or dissection can initially be diagnosed on a TTE. This modality is somewhat limited in that it yields finite views of the aorta and is dependent on the skill of the sonographer and patient habitus. A transesophageal echocardiogram can give more comprehensive views and does not have the same limitation of patient habitus. For viewing the entirety of the aorta, computed tomography (CT) with contrast as well as magnetic resonance imaging (MRI) with gadolinium contrast are most often used and can be used in comparison when serial imaging is completed for surveillance. The normal aortic diameter for a patient is variable based on age, gender, and body surface area.^{9,10}

Medical treatment for patients with both aneurysms and dissection starts with reducing blood pressure, controlling lipids, and smoking cessation. Patients should be cautioned against strenuous exercise. Beta-blockers are often used in aneurysms with conflicting information showing the extent of benefit.¹⁰⁻¹² Once dissection has developed, there is reportedly a distinct survival benefit associated with beta-blocker administration.¹³ Multiple trials have assessed the efficacy of angiotensin II receptor blockers (ARBs) on reducing aortic growth.¹⁴⁻¹⁶ So far, the studies have shown less expansion of aortic growth when patients are treated with ARBs; however, most studies were limited to patients with Marfan's syndrome.

Surgical therapies for dissection were first developed in the 1950s and have evolved significantly since then, with endovascular repair now an option for certain patients. Studies have shown that the risk of rupture with dissection increased sharply with aortic diameters >6cm at the ascending aorta and >7cm at the descending aorta. Thus, many professional societies recommend 5.5cm as the threshold for surgical referral in asymptomatic patients, and even earlier if there is a defined genetic disorder, especially with a family history of dissection.^{9,17-20}

The questions I had regarding my asymptomatic patient were: what was the best initial screening algorithm for this asymptomatic patient and what should I do for further surveillance if these results were normal? After reviewing the available data, I sent the patient for a transthoracic echocardiogram to assess the structure and integrity of the aortic valve and proximal aorta. I also requested a CT scan of the aorta with contrast to evaluate the dimensions of the aorta. These both returned normal, with a well-functioning aortic valve visualized on TTE and a normal-sized aorta without dissection seen on CT. I discussed genetic testing for the patient, which she declined.

The plan was for follow-up in the office in 6 months with subsequent imaging. One month after the initial visit and imaging, I received notification that the patient had died suddenly of an aortic dissection.

As vascular Ehlers-Danlos is a rare but usually fatal genetic disorder at a young age, it is difficult to generate large study populations to evaluate optimal surveillance, treatment, and outcomes of these patients. The patient's son is being closely followed and we have recommended that all relatives be screened as well.

REFERENCES

1. **Howard DP, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM; Oxford Vascular Study.** Population-based study of incidence and outcome of acute aortic dissection and premorbid risk factor control: 10-year results from the Oxford Vascular Study. *Circulation*. 2013 May 21;127(20):2031-7. doi:10.1161/CIRCULATIONAHA.112.000483. Epub 2013 Apr 18. PubMed PMID: 23599348.
2. **Jones JA, Stroud RE, O'Quinn EC, Black LE, Barth JL, Eleftheriades JA, Bavaria JE, Gorman JH 3rd, Gorman RC, Spinale FG, Ikonomidis JS.** Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. *Circ Cardiovasc Genet*. 2011 Dec;4(6):605-13. doi:10.1161/CIRCGENETICS.111.960419. Epub 2011 Oct 18. PubMed PMID: 22010139; PubMed Central PMCID: PMC3246193.
3. **Ikonomidis JS, Ivey CR, Wheeler JB, Akerman AW, Rice A, Patel RK, Stroud RE, Shah AA, Hughes CG, Ferrari G, Mukherjee R, Jones JA.** Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease. *J Thorac Cardiovasc Surg*. 2013 May; 145(5):1326-33. doi: 10.1016/j.jtcvs.2012.12.027. Epub 2013 Jan 11. PubMed PMID: 23312977; PubMed Central PMCID: PMC4057430.
4. **Pope FM, Martin GR, Lichtenstein JR, Penttinen R, Gerson B, Rowe DW, McKusick VA.** Patients with Ehlers-Danlos syndrome type IV lack type III collagen. *Proc Natl Acad Sci USA*. 1975 Apr; 72(4):1314-6. PubMed PMID: 1055406; PubMed Central PMCID: PMC432523.
5. **Pepin MG, Schwarze U, Rice KM, Liu M, Leistriz D, Byers PH.** Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). *Genet Med*. 2014 Dec; 16(12):881-8. doi:10.1038/gim.2014.72. Epub 2014 Jun 12. PubMed PMID: 24922459.
6. **Frank M, Says J, Denarié N, Messas E.** Natural history of superficial venous insufficiency in patients with vascular Ehlers-Danlos syndrome. *Phleb Ann Vasc*. 2015b; 68:34-40.
7. **Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V.** Thoracic aortic aneurysm and dissection. *J Am Coll Cardiol*. 2014 Oct 21;64(16):1725-39. doi: 10.1016/j.jacc.2014.08.025. Review. PubMed PMID: 25323262.
8. **Pepin M, Schwarze U, Superti-Furga A, Byers PH.** Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. *N Engl J Med*. 2000 Mar 9; 342(10):673-80. Erratum in: *N Engl J Med* 2001 Feb 1; 344(5):392. PubMed PMID: 10706896.
9. **Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American College of Radiology; American Stroke Association; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of Thoracic Surgeons; Society for Vascular Medicine.** 2010ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM. Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *J Am Coll Cardiol*. 2010 Apr 6;55(14):e27-e129. doi:10.1016/j.jacc.2010.02.015. Erratum in: *J Am Coll Cardiol*. 2013 Sep 10;62(11):1039-40. PubMed PMID: 20359588.
10. **Eleftheriades JA, Farkas EA.** Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. *J Am Coll Cardiol*. 2010 Mar 2;55(9):841-57. doi:10.1016/j.jacc.2009.08.084. Review. PubMed PMID: 20185035.
11. **Gersony DR, McClaughlin MA, Jin Z, Gersony WM.** The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis. *Int J Cardiol*. 2007 Jan 18;114(3):303-8. Epub 2006 Jul 10. PubMed PMID: 16831475.
12. **Ladouceur M, Fermanian C, Lupoglazoff JM, Edouard T, Dulac Y, Acar P, Magnier S, Jondeau G.** Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. *Am J Cardiol*. 2007 Feb 1;99(3):406-9. Epub 2006 Dec 14. PubMed PMID: 17261408.
13. **Suzuki T, Isselbacher EM, Nienaber CA, Pyeritz RE, Eagle KA, Tsai TT, Cooper JV, Januzzi JL Jr, Braverman AC, Montgomery DG, Fattori R, Pape L, Harris KM, Booher A, Oh JK, Peterson M, Ramanath VS, Froehlich JB; IRAD Investigators.** Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]). *Am J Cardiol*. 2012 Jan 1; 109(1):122-7. doi: 10.1016/j.amjcard.2011.08.012. Epub 2011 Sep 23. PubMed PMID: 21944678.
14. **Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd.** Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med*. 2008 Jun

- 26; 358(26):2787-95. doi: 10.1056/NEJMoa0706585. PubMed PMID: 18579813; PubMed Central PMCID: PMC2692965.
15. **Pees C, Laccone F, Hagl M, Debrauwer V, Moser E, Michel-Behnke I.** Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. *Am J Cardiol.* 2013 Nov 1; 112(9):1477-83. doi: 10.1016/j.amjcard.2013.06.019. Epub 2013 Jul 19. PubMed PMID: 23871676.
 16. **Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ.** Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. *Eur Heart J.* 2013 Dec;34(45):3491-500. doi:10.1093/eurheartj/eh334. Epub 2013 Sep 2. PubMed PMID: 23999449.
 17. **Elefteriades JA.** Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. *Ann Thorac Surg.* 2002 Nov;74(5):S1877-80; discussion S1892-8. PubMed PMID: 12440685.
 18. **Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, Elefteriades JA.** What is the appropriate size criterion for resection of thoracic aortic aneurysms? *J Thorac Cardiovasc Surg.* 1997 Mar;113(3):476-91; discussion 489-91. PubMed PMID: 9081092.
 19. **Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, Elefteriades JA.** Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. *Ann Thorac Surg.* 2002 Jan;73(1):17-27; discussion 27-8. PubMed PMID: 11834007.
 20. **Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC.** Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. *Science.* 2006 Apr 7;312(5770):117-21. PubMed PMID: 16601194; PubMed Central PMCID: PMC1482474.